Azetukalner advances toward FDA submission as pain pipeline matures.

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter. Chief Executive Offi

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared construct

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Xenon Pharmaceuticals Inc (XENE) reports robust pipeline progress and $1.2 billion in cash, funding operations into 2029 as it prepares for regulatory submission.

With EPS growth for the next five years forecasted at 31.63%, Biohaven Ltd. (NYSE:BHVN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 29, BofA downgraded Biohaven Ltd. (NYSE:BHVN) to Underperform from Neutral and lowered its price target to $11 from $12, citing a more cautious view of the […]

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.

Xenon Pharmaceuticals stock performance snapshot Xenon Pharmaceuticals (XENE) shares closed at US$51.34, with the stock down around 3% over the past day and about 4% over the past week, extending a weaker month and past 3 months. See our latest analysis for Xenon Pharmaceuticals. The recent slide, including a 7.96% 1 month share price decline and 11.33% 3 month share price decline, contrasts with a stronger backdrop. Year to date share price return of 15.40% and a 1 year total shareholder...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is one of the 10 Best Performing Canadian Stocks So Far in 2026. On May 12, 2026, JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to $80 from $77 and maintained an Overweight rating on the shares. Wells Fargo analyst Benjamin Burnett also raised the […]

Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.